01.28.25 -- Considerations For Early Stage Companies

This study demonstrates the Korus platform's ability to reduce manufacturing variability by elutriating lymphocytes from apheresis, providing a more consistent cell product for downstream manufacturing.

This presentation explores natural killer (NK) cells and how conditions for electroporating primary NK cells can be optimized to improve cell viability, transfection efficiency, and other factors.

Which production model is best suited for your cell and gene therapies, Point-of-Care (PoC) or Decentralized Manufacturing? Explore the impact of both approaches.

For many applications, cutting-edge centrifugation technologies can achieve cell harvest optimization, providing a low-shear, high-yield process that is tightly controlled and highly reproducible.

Modifying natural killer (NK) cells with chimeric antigen receptors (CARs) can further enhance their anti-tumor efficacy. Here, we present an automated process for CAR NK cell generation.

Efficient quality control of therapeutic oligonucleotides is crucial. Explore advanced methods combining HPLC-UV and mass spectrometry for precise impurity quantification and mass confirmation.

Compare single-use system bags, focusing on their design, materials, and applications to better understand why controlling particulate levels is critical to maintaining product purity and efficacy.

This paper underscores the 4D-Nucleofector® LV Unit as a pivotal tool for translating genetic modification technologies into scalable, safe, and effective therapeutic solutions.